For laboratory research use only — not for human or veterinary consumption.
The Peptide Index
Dosing guide

B7-33 Dosage Chart & Schedule

B7-33 is a single-chain peptide analog of human relaxin-2 engineered to retain relaxin anti-fibrotic activity in a simpler, more synthesizable molecule. It is a preclinical research reagent studied in models of cardiac, lung, and kidney fibrosis, with no human trials and no approved use.

Route
Subcutaneous
Frequency
No established dosing
Half-life
Short
Storage
Lyophilized: cool or frozen. Reconstituted: refrigerate 2-8 C.
The short answer

B7-33 is a single-chain relaxin-2 peptide analog studied only in preclinical fibrosis and injury models by injection. It has no human trials and no approved use, so no validated human dosing exists; any figure is animal-model context only.

Figures describe how B7-33 is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.

Dosage protocols

Commonly referenced research tiers. Start conservative; every compound and study context differs.

Most commonStandard
No established dose
Studied only in animal models by injection
Frequency
Not established in humans
Weekly total
Not established in humans
Cycle
Preclinical only; no human trials

Reported context only; no validated human dosing exists.

Preclinical only

  • B7-33 has no human trials and no approved use.
  • It has been studied only in animal fibrosis and injury models, by injection.
  • No validated human dose exists.

Relaxin-2 analog

  • It is a single-chain analog of relaxin-2 acting as a biased RXFP1 agonist.
  • It is engineered to keep anti-fibrotic activity in a simpler, more synthesizable molecule.

Ready to run this protocol?

Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.

From vial to injection in 6 steps

1

Wipe both vial tops

Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.

2

Draw the water

Pull the planned amount of bacteriostatic water (2 mL) into the syringe.

3

Add it slowly

Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.

4

Let it dissolve

Wait until the solution is fully clear, then refrigerate the vial.

5

Draw your dose

Pull the calculated units on a U-100 insulin syringe.

6

Store between uses

Keep the reconstituted vial refrigerated and use within its stable window.

Handling & storage

  • A 5 mg vial with 2 mL bacteriostatic water gives 2,500 mcg/mL; one U-100 unit is about 25 mcg.
  • Reconstitute gently and refrigerate; the peptide is short-acting in solution.
  • All handling references are for research use; no human protocol exists.
  • Its relative serelaxin was dosed by IV infusion rather than subcutaneously.

B7-33 dosing FAQ

Is there a human dose for B7-33?

No. B7-33 has been studied only in animal fibrosis and injury models by injection; there is no approved or validated human dosing.

How is it related to serelaxin?

Both act on the RXFP1 relaxin receptor, but B7-33 is a simplified single-chain relaxin-2 analog, while serelaxin is full recombinant relaxin-2 given by IV infusion.

How short-acting is it?

Preclinical work reports a half-life on the order of minutes, so any dosing reference is animal-model context only.

What would a research reconstitution look like?

As an illustration only, a 5 mg vial with 2 mL bacteriostatic water is 2,500 mcg/mL (about 25 mcg per U-100 unit). This is handling context, not a dose.

Sources

Full B7-33 reference →All dosing charts →

Categories: Healing & Recovery · Status: Research use only. This page is educational and for laboratory research use only; it is not medical advice.